[EN] NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) [FR] MODULATEURS SELECTIFS DU RECEPTEUR D'ANDROGENE A BASE DE DERIVES BENZIMIDAZOLIQUES
Novel benzimidazole derivatives useful as selective androgen receptor modulators (SARMS)
申请人:Ng Raymond
公开号:US20060111402A1
公开(公告)日:2006-05-25
The present invention is directed to novel benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.
本发明涉及新型苯并咪唑衍生物、包含它们的药物组合物及其在调节雄激素受体所致的疾病和症状中的应用。
Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms)
申请人:Ng Raymond
公开号:US20060116412A1
公开(公告)日:2006-06-01
The present invention is directed to novel benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.
本发明涉及新的苯并咪唑衍生物、包含它们的药物组合物及其在治疗由雄激素受体调节的疾病和症状中的应用。
Novel Benzimidazole Derivatives Useful as Selective Androgen Receptor Modulators (SARMS)
申请人:Ng Raymond
公开号:US20090258909A1
公开(公告)日:2009-10-15
The present invention is directed to novel benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.
NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS)
申请人:Ng Raymond
公开号:US20080119522A1
公开(公告)日:2008-05-22
The present invention is directed to novel benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.
MEDICINAL COMPOSITION FOR INHIBITING AMYLOID- PROTEIN DEPOSITION
申请人:Sumitomo Chemical Company, Limited
公开号:EP2246334A1
公开(公告)日:2010-11-03
The present invention provides: a pharmaceutical composition for inhibiting amyloid-β protein accumulation comprising a compound of the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient; a method for inhibiting amyloid-β protein accumulation, comprising a step of administering an effective amount of the compound of the formula (I) or a pharmaceutically acceptable salt thereof to a mammal which may be diagnosed with an amyloid-β protein-related disease; and so on.